Clinical trial NCT02304081 - References

Type2 Diabetes Mellitus — Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Citation(s)

•   Chen L, Klein T, Leung PS
  Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med. 2012 Sep;12(8):995-1004.
•   Cobb J, Gall W, Adam KP, Nakhle P, Button E, Hathorn J, Lawton K, Milburn M, Perichon R, Mitchell M, Natali A, Ferrannini E
  A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol. 2013 Jan 1;7(1):100-10.
•   Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ
  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Ja
•   Forst T, Anastassiadis E, Diessel S, Löffler A, Pfützner A
  Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoin
•   Forst T, Dworak M, Berndt-Zipfel C, Löffler A, Klamp I, Mitry M, Pfützner A
  Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the ß cell of patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Jun;15(6):
•   Kurosaki E, Ogasawara H
  Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 A
•   List JF, Woo V, Morales E, Tang W, Fiedorek FT
  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009 Apr;32(4):650-7. doi: 10.2337/dc08-1863. Epub 2008 Dec 29.
•   Liu D, Moberg E, Kollind M, Lins PE, Adamson U, Macdonald IA
  Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia and hypoglycaemia. Diabetologia. 1992 Mar;35(3):287-90.
•   McGuire EA, Helderman JH, Tobin JD, Andres R, Berman M
  Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 1976 Oct;41(4):565-73.
•   Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA
  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 Feb;124(2
•   Rosenstock J, Vico M, Wei L, Salsali A, List JF
  Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul;35(
•   Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M
  Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosi
•   Zhang Y, Chi J, Wang W, Hong J, Gu W, Wang B, Ning G
  Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on ß-cell function in a newly designed two-step hyperglycemic clamp. J Diabetes. 2015 Mar;7(2):213-21. doi: 10.1111/1753-0407.

Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment

Details for clinical trial NCT02304081